- Home
- NMM vs PCRX Comparison
NMM vs PCRX Comparison
Compare NMM & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMM
- PCRX
- Stock Information
- Founded
- NMM 2007
- PCRX 2006
- Country
- NMM Monaco
- PCRX United States
- Employees
- NMM N/A
- PCRX N/A
- Industry
- NMM Marine Transportation
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- NMM Consumer Discretionary
- PCRX Health Care
- Exchange
- NMM Nasdaq
- PCRX Nasdaq
- Market Cap
- NMM 1.3B
- PCRX 1.1B
- IPO Year
- NMM 2007
- PCRX 2011
- Fundamental
- Price
- NMM $39.46
- PCRX $24.24
- Analyst Decision
- NMM Strong Buy
- PCRX Buy
- Analyst Count
- NMM 1
- PCRX 9
- Target Price
- NMM $80.00
- PCRX $30.67
- AVG Volume (30 Days)
- NMM 76.7K
- PCRX 839.2K
- Earning Date
- NMM 05-13-2025
- PCRX 05-06-2025
- Dividend Yield
- NMM 0.51%
- PCRX N/A
- EPS Growth
- NMM N/A
- PCRX N/A
- EPS
- NMM 12.15
- PCRX N/A
- Revenue
- NMM $1,334,066,000.00
- PCRX $700,966,000.00
- Revenue This Year
- NMM N/A
- PCRX $9.37
- Revenue Next Year
- NMM $6.96
- PCRX $11.30
- P/E Ratio
- NMM $3.20
- PCRX N/A
- Revenue Growth
- NMM 2.08
- PCRX 3.85
- 52 Week Low
- NMM $37.75
- PCRX $11.16
- 52 Week High
- NMM $65.89
- PCRX $31.67
- Technical
- Relative Strength Index (RSI)
- NMM 42.04
- PCRX 52.60
- Support Level
- NMM $37.85
- PCRX $23.93
- Resistance Level
- NMM $39.79
- PCRX $25.88
- Average True Range (ATR)
- NMM 1.20
- PCRX 0.89
- MACD
- NMM 0.04
- PCRX 0.15
- Stochastic Oscillator
- NMM 41.60
- PCRX 65.45
About NMM Navios Maritime Partners LP Common Units Representing Limited Partner Interests
Navios Maritime Partners LP is a seaborne shipping company. It owns and operates dry cargo and container vessels with the primary long-term and staggered expiration charters. The firm's fleet consists of Ultra- Handymax, Panamax, Capsize, and Container vessels and categorized in Drybulk and Container vessels. It earns revenue through chartering of vessels, voyage contracts. Geographically, it generates majority revenue from Asia.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.